About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online in JAMA Oncology. CLL is the most prevalent…
Source:CLL patients discontinue ibrutinib drug due to disease progression during clinical trials
Saturday, February 28, 2015
CLL patients discontinue ibrutinib drug due to disease progression during clinical trials
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment